Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor 
BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Ohashi, Kadaoki; Sequist, Lecia V.; Moran, Teresa; Chmielecki, Juliann; Lin, Ya-Lun; Pan, Yumei; Wang, Lu; de Stanchina, Elisa; Shien, Kazuhiko; Aoe, Keisuke; Toyooka, Shinichi; Kiura, Katsuyuki; Fernandez-Cuesta, Lynnette; Fidias, Panos; Yang, James Chih-Hsin; Miller, Vincent A.; Riely, Gregory J.; Kris, Mark G.; Engelman, Jeffrey A.; Vnencak-Jones, Xindy L.; Dias-Santagata, Dora; Ladanyi, Marc; Pao, William

doi:10.1073/pnas.1203530109

Lokale TagsFreigabegeschichteDetailsÜbersicht

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Ohashi, K., Sequist, L. V., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., et al. (2012). Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America, 109(31), E2127-E2133. doi:10.1073/pnas.1203530109.

Item is Freigegeben

einblenden: alle ausblenden: alle

Basisdaten

einblenden: ausblenden:

Datensatz-Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D68B-C Versions-Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D68C-A

Genre: Zeitschriftenartikel

ausblenden:

Urheber:
Ohashi, Kadaoki¹, Autor
Sequist, Lecia V.¹, Autor
Moran, Teresa¹, Autor
Chmielecki, Juliann¹, Autor
Lin, Ya-Lun¹, Autor
Pan, Yumei¹, Autor
Wang, Lu¹, Autor
de Stanchina, Elisa¹, Autor
Shien, Kazuhiko¹, Autor
Aoe, Keisuke¹, Autor
Toyooka, Shinichi¹, Autor
Kiura, Katsuyuki¹, Autor
Fernandez-Cuesta, Lynnette², Autor
Fidias, Panos¹, Autor
Yang, James Chih-Hsin¹, Autor
Miller, Vincent A.¹, Autor
Riely, Gregory J.¹, Autor
Kris, Mark G.¹, Autor
Engelman, Jeffrey A.¹, Autor
Vnencak-Jones, Xindy L.¹, Autor
Dias-Santagata, Dora¹, AutorLadanyi, Marc¹, AutorPao, William¹, Autor mehr..

Affiliations:
1a Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, United States b Massachusetts General Hospital Cancer Center, Boston, MA 02114, United States c Department of Medicine, Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Harvard Medical School, Boston, MA 02115, United States e Department of Pathology, New York, NY 10065, United States f Anti-Tumor Assessment Core Facility, New York, NY 10065, United States g Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, United States h Catalan Institute of Oncology, Universitat Autonoma de Barcelona, Hospital Universitari Germans Trias I Pujol, 08916 Badalona, Barcelona, Spain i Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, United States j Department of Thoracic Surgery, Okayama University Hospital, Okayama, Okayama, Japan k Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi 755-0241, Japan l Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi 755-0241, Japan m Department of Hematology, Oncology, and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Okayama 700-8558, Japan n Graduate Institute of Oncology, Taiwan o Cancer Research Center, National Taiwan University, Taipei 100, Taiwan p Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, United States q Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, United States, ou_persistent22
2Max Planck Society, ou_persistent13